Pay in 4 interest-free payments of $6.21 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
These cancers comprise about 40% of all cancers diagnosed in the United States each year (3 Trusted Source Obesity and overweight Go to source)
However, in the pivotal Phase IIb trial, it failed to demonstrate statistically significant weight loss compared to placebo at the primary endpoint, leading the developer (Metabolic Pharmaceuticals Ltd.) to terminate the commercial program
The components are nutrients and amino acids, and the injections are well tolerated by most patients
A flurry of other recent publications also show relatively high percentages of patients dropping out as early as four weeks into treatment and that discontinuation increases over time, often before patients reach a clinically meaningful level of weight loss
Kapitza C, Zdravkovic M, Zijlstra E, Segel S, Heise T, Flint A
US$ 28.95
US$ 25.74
US$ 29.55
US$ 24.60
US$ 27.35
US$ 22.85
US$ 22.46
US$ 29.60
US$ 29.77
US$ 23.23
US$ 27.77
US$ 25.64
